A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
ConditionGlioblastoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma.
The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Eligibility criteria
Qualifiers
Age ≥18 years
Karnofsky Performance Status (KPS) of 60 or greater
Recurrent supratentorial Glioblastoma that has progressed following standard therapy; patients must have previously been treated with radiation with or without temozolomide.
Patients will be eligible at first or second recurrence.
Disqualifiers
Major surgical procedures or serious trauma, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator).
Currently pregnant or breastfeeding.
Note: Patients with clinically asymptomatic presence of hemosiderin, resolving postoperative changes or punctate intratumoral hemorrhage are permitted
Gastrointestinal bleeding
Trial design
Treatments tested in this trial
- Ivonescimab
Treatment groups
45 Participants
are divided into 1 treatment groupSponsors and collaborators
M.D. Anderson Cancer Center
Lead sponsor
Summit Therapeutics
Collaborator
Source ClinicalTrials.gov